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Abstract
CD4+ regulatory T cells (Tregs) are essential for normal immune surveillance, and their
dysfunction can lead the development of autoimmune diseases. Pluripotent stem cells
(PSCs) can be utilized to obtain a renewable source of healthy Tregs to treat autoim‐
mune disorders as they have the ability to produce almost all cell types in the body,
including Tregs. However, the right conditions for the development of antigen (Ag)-
specific Tregs from PSCs (i.e., PSC-Tregs) have not been fully defined, especially the
signaling mechanisms that the direct differentiation of such Tregs. Ag-specific PSC-
Tregs  can  be  tissue-associated  and  infiltrate  to  local  inflamed  tissue  to  suppress
autoimmune  responses  after  adoptive  transfer,  thereby  avoiding  potential  overall
immunosuppression  from non-specific  Tregs.  Development  of  cell-based  therapies
using  Ag-specific  PSC-Tregs  will  provide  an  important  step  toward  personalized
therapies for autoimmune disorders.
Keywords: regulatory T cells, pluripotent state cells, cell differentiation, immunother‐
apy, autoimmunity
1. Introduction
Regulatory T cells (Tregs) are a component of the normal immune system and contribute to the
maintenance of peripheral tolerance. Tregs are defined phenotypically by the expression of the
interleukin (IL)-2 receptor α-chain (CD25) and the transcriptional factor, forkhead box P3
(FoxP3), which is required for the Treg development and controls a genetic program specify‐
ing cell  fate.  Tregs  can down-regulate  immune responses  and are  essential  for  immune
homeostasis [1]. Tregs are key effectors in preventing and treating autoimmune disorders, for
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example, rheumatoid arthritis (RA), type 1 diabetes (T1D), and inflammatory bowel diseases
(IBD), and controlling both the transplant rejection graft-versus-host disease (GVHD) [2–5].
Tregs or suppressors of T cells, as they had been originally named, have been studied since
early 1970s. In 1970, Gershon and Kondo reported that T cells not only augmented but also
have the ability to dampen immune responses. The immune dampening was mediated by a
special class of T cells that were different from helper T cells; this special type of T-cell
population is known as suppressor T cells and is found in CD4+ population [6]. It is well
understood that CD4+ Tregs are essential for normal immunological self-tolerance and immune
homeostasis. Failure of immunologic self-tolerance often leads to the development of autoim‐
mune disorders, which are estimated to afflict up to 5% of the population. Although there are
a number of debates regarding the etiology of autoimmune diseases, it is well documented
that T cells are the key mediators of many autoimmune disorders, such as autoimmune
arthritis, autoimmune thyroiditis, and insulin-dependent diabetes mellitus (IDDM). There are
various mechanisms for establishing and sustaining immunological self-tolerance and
immune homeostasis. In addition to these, T cell-mediated suppression of immune respons‐
es toward self and non-self antigens (Ags) has recently attracted enormous interest [7]. T-cell–
mediated suppression is mainly achieved by FoxP3+ Tregs, which play an important role in
the prevention and suppression of autoimmunity. The deficiencies in Treg function have been
identified in a wide variety of human autoimmune disorders, such as IPEX (immunodysre‐
gulation polyendocrinopathy enteropathy X-linked syndrome) [8–10]. As the Treg numbers
are important for effective suppressive function, adoptive transfer of exogenous Tregs would
be ideal for the treatment of autoimmunity or Treg-deficient diseases.
Tregs comprise of 5–10% of the mature CD4+ T helper cell subpopulation in mice and about
1–2% of CD4+ T cells in human. As a result, it is crucial to develop large numbers of Tregs in
vitro and adoptively transfer them for cell-based therapies. There has been no approach
described for isolating a large number of Tregs with % specificity. Therefore, the attention has
now been focused on utilizing pluripotent stem cells (PSCs) as a source for obtaining Ag-
specific Tregs. PSCs can be utilized to obtain a renewable source of healthy Tregs to treat
autoimmune disorders as they have the ability to produce almost all cell types in the body,
including Tregs. However, optimal conditions and signaling network for the development and
differentiation of Ag-specific Tregs from PSCs (i.e., PSC-Tregs) have not been fully defined [11].
Ag-specific PSC-Tregs serve as a better choice of Tregs for cell-based therapies as they can
accumulate in local inflamed tissues to suppress autoimmune responses after adoptive
transfer, thereby avoiding potential overall immunosuppression from non-specific Tregs.
2. CD4+ and CD8+ Tregs
Tregs are an integral component of the normal immune system and contribute to the mainte‐
nance of peripheral tolerance. Tregs can down-regulate immune responses and are essential
for immune homeostasis. There are two major classes of Tregs: CD4+ and CD8+ Tregs. CD4+
Tregs consists of two types: Naturally occurring Tregs (nTregs) that is characterized by
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constitutively expression of CD25 and FoxP3, and adaptive or inducible Tregs (iTregs) that are
induced upon persistent Ag exposure in the periphery.
nTregs develop in the thymus. nTregs originate as CD4+ cells which highly express CD25, the
alpha chain of the IL-2 receptor, and the transcription factor FoxP3. Of the total CD4+ T-cell
population, approximately 5–10% are nTregs, which can be visualized at the single-positive
(SP) stage of development in the thymus [12]. nTregs are positively selected in the thymus and
represent the thymocytes with a relatively high avidity for self-Ags. The signals for the
development of Tregs are the interaction between the T-cell receptor (TCR) and the complex
of MHC (major histocompatibility complex) class II molecules with self-peptide expressed on
the thymic stroma [13]. It is also known that nTregs are essentially cytokine independent
during the development.
iTregs originate from the thymus as a single-positive CD4+ cells. They differentiate into CD25-
and FoxP3-expressing Tregs following adequate antigenic stimulation in the presence of
cognate Ag and specialized immune-regulatory cytokines, such as TGF-β, IL-10, and IL-4
[14].
3. Treg development
Till today, several models have been proposed for the development of Tregs in the thymus.
The interaction of costimulatory molecule CD28 and its B7 family member ligands is impor‐
tant for the development of nTreg in the thymus. CD28 ligand B7.1 and B7.2 are primarily
expressed on thymic antigen-presenting cells (APCs), including dendritic cells (DCs), and
epithelial cells. Although the role of this costimulation in the development of nTregs is not
clear, it has been reported that mice deficient in the costimulatory molecule CD28 or CD28
ligands B7.1/B7.2 has decreased numbers and percentages of thymic nTregs [15–17]. One
possible function is that they provide a quantitative signal along with TCR stimulation that
drives T cells to develop into nTregs. This costimulation has the ability to function in prevent‐
ing negative selection and supporting nTreg development [18]. NF-κB is a transcription factor
that functions the downstream of the CD28/B7 costimulation. NF-κB family member c-Rel has
been shown to be a critical factor for the development of nTregs in the thymus [19]. TCR
engagement leads to the expression of high-affinity IL-2 receptor (CD25), which causes IL-2-
induced FoxP3 expression and nTreg commitment [20]. Published evidence showed that IL-2-
deficient mice exhibited 50% reduction of nTregs in the thymus [21]. Therefore, IL-2 is an
important cytokine required for the development of nTregs. FoxP3 is another important
transcription factor for the development of nTregs. Mice deficient in FoxP3 or harboring a
mutated FoxP3 gene developed lethal multi-organ inflammation. Adoptive transfer of FoxP3+
T cells into neonates protected FoxP3-deficient mice from their autoimmune pathology [22,
23]. Clearly, FoxP3 is required for the nTreg development and affects its functional activity.
Hematopoietic stem cell (HSC)-derived hematopoietic progenitors migrate into the thymus
and develop into different types of T cells. The development of αβ T cells in the thymus is a
highly ordered process. The most immature thymocyte population (CD4−CD8−) is referred to
as double negative (DN) cells. DN precursors are subdivided into sequential developmental
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subsets as follows: DN1 (CD44+CD25−), DN2 (CD44+CD25+), DN3 (CD44−CD25+), and DN4
(CD44−CD25−). Recombination activating genes (Rag), including Rag1 and Rag2 catalyze the
TCRβ locus for rearrangement, which is initiated during cell transit from the DN2 to the DN3
stage. A functional TCR β chain generated only in DN3 cells has the ability to pair with the
invariant pre-Tα/CD3 and create a pre-TCR. The DNs cells with pre-TCR are selected and can
continue to differentiate to DN4. This episode is called β-selection, which is the initial
checkpoint of T lymphocyte differentiation in the thymus. Pre-TCR formation in DN4 cells
drives cell differentiation and ends the rearrangement of TCRβ locus, resulting in the
development of the CD4+CD8+ double positive (DP) cells from DN4 cells [24].
In summary, the Treg development within the thymus includes a series of processes—positive
selection (e.g., TCR rearrangement) and negative selection (e.g., clonal deletion) [25]. The
autoimmune regulator Aire (largely expressed in thymic medullary epithelial cells—TECs)
[26] and FoxP3 have key functions in clonal deletion and Treg selection [27, 28]. There are links
among Aire expression, FoxP3 up-regulation, and Treg selection [29–31]. Evidence suggests
that Aire deficiency affects the negative selection of self-reactive T cells and FoxP3 controls the
development and function of the nTregs [29].
4. Ag-specific induction of Tregs
The mechanisms of acquisition of self-tolerance by the immune system are still being investi‐
gated. However, a widely accepted mechanism is the deletion of immature thymocytes before
acquiring functional maturity in the thymic cortex and medulla [32, 33]. However, some self-
reactive cells can escape to the periphery by breaking central tolerance [34, 35]. It is possible
that such cells contain TCRs that recognize weak self-epitopes and as such, these autoreac‐
tive cells require peripheral tolerance to counteract them. Maintenance of peripheral toler‐
ance, such as the deletion or reversible anergy of T cells, is performed by Tregs [36, 37]. The
identification and characterization of Tregs definitively confirmed the existence of dominant
tolerance [23, 38, 39]. Generating the peripheral Tregs in diverse microenvironments, for
example, the gut, as well as the specific locations with tumors or microbes maintains local
homeostasis. Tregs engendered in the peripheral tissue, external of the thymus, stay by way
of resting cells on inter-mitotic phase, self-regulating further supply of agonist ligand which
drives the formation of Tregs. This critical feature of the immune system lets the Tregs an
approaching production to conquer undesirable immunity. As soon as encountering agonist
TCR ligand, Tregs have the ability to migrate to Ag-draining lymph nodes in which Tregs
undertake substantial expansion [40, 41]. The specificity of Treg-mediated suppression results
from the corecruitment of Tregs and other T cells in Ag-draining lymph nodes. As a result,
Tregs with certain specificity have the ability to suppress various effector cells through
distinctive specificity when restricted in the area of identical APCs [42, 43]. At locations of
inflammation, suppressive function, including the suppression of Th1 and Th17 responses,
needs Tregs’ trafficking and migration in tissues and secondary or peripheral lymphoid
organs, such as lymph nodes and the spleen [44]. In addition, compared with naive or activated
T cells, FoxP3-expressing Tregs have a distinct transcriptional profiling, showing a different
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number of differentially expressed genes, including certain genes generally up-regulated in
activated T cells, for example, IL2ra, Ctla4, and Tnfrsf18, which individually contribute CD25,
CTLA4, and glucocorticoid-induced TNF receptor (GITR). Therefore, these target genes
represent the transcriptional induction of the Treg signature by FoxP3 [45, 46].
5. Treg-mediated suppression
Tregs play an important role in the maintenance of immune tolerance. Sakaguchi and
colleagues first described the importance of Tregs in the prevention of autoimmune disease
development. They demonstrated that adoptive transfer of CD4+ T cells, depleted of CD25+ T
cells by a specific monoclonal antibody against CD25 into BALB/c athymic nude mice, caused
spontaneous development of T-cell–mediated autoimmune disease [47]. When these mice
were reconstituted with CD4+CD25+ T cells, the autoimmune disease development was
successfully ameliorated within a brief period post transfer. The discovery of the X chromo‐
some-encoded transcription factor FoxP3 as a specification and maintenance factor subse‐
quently confirmed CD4+CD25+ T cells as a unique thymus-derived lineage. Examining their
role in the murine immune system revealed that Tregs have a central role in immune homeo‐
stasis: Genetic defects resulting in the dysfunctional Tregs result in multi-organ autoim‐
mune disease, and the depletion of nTregs induces autoimmunity. The next question to be
addressed is to define the mechanisms of Treg-mediated suppression. It has already been
established that Foxp3+CD25+CD4+ nTregs suppress the proliferation of naive T cells and their
differentiation to effector T cells in vivo. They also have the ability to suppress effector activities
of differentiated CD4+ and CD8+ T cells and the function of natural killer (NK) cells, natural
killer T (NKT) cells, B cells, macrophages, osteoclasts, and DCs [48–50]. Tregs suppress the
proliferation and cytokine production (in particular of IL-2) of responder T cells when the two
populations are cocultured in vitro and stimulated by Ag in the presence of APCs [51]. Once
activated by a particular Ag, Tregs can suppress responder T cells irrespective of whether they
share Ag specificity with the Treg [52].
Several mechanisms of Treg-mediated suppression have been proposed, including the
secretion of immunosuppressive cytokines, cell contact-dependent suppression, and func‐
tional modification or killing of APCs. For example, IL-10 and TGF-β contribute to the
suppression of arthritis in Ag-induced arthritis mice [11]. Another study showed that IL-10
and TGF-β contribute to the suppression of IBD induced in mice by Treg depletion [53].
Another mechanism for the killing of responder T cells or APCs is cell-to-cell contact. Tregs
can secrete granzyme or perforin to destroy target T cells or APCs by cell-to-cell interaction
method, or deliver a negative signal by CTLA-4 or FasL to responder T cells. Potential critical
signals involve up-regulation of intracellular cyclic adenosine monophosphate (cAMP) that
results in the suppression of T-cell proliferation and cytokine production, such as IL-2, or the
production of pericellular adenosine catalyzed by CD39, that is, ectonucleoside triphosphate
diphosphohydrolase 1, and CD73, that is, ecto-5′-nucleotidase, which are presented through
Tregs [50]. Activated Tregs can cause down-regulation of CD80/86 expression on APCs or
stimulate DCs to form the enzyme indoleamine 2,3-dioxygenase, which catabolizes the
essential amino acid tryptophan to kynurenines, causing toxicity to T cells. All these func‐
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tions are dependent on the expression of CTLA-4 on Tregs. Treg-mediated suppression can
occur (1) via Ag-specific Tregs upon antigenic stimulation, which is highly mobile and swiftly
recruited at the site of inflammation; (2) Ag-activated Tregs contacting DCs that restrict DC
function, thereby hindering the activation of other T cells; and (3) through the secretion of
granzyme/perforin, IL-10, or other immune suppressive cytokines, such as IL-35, depending
on the strength and duration of antigenic stimulation and the local milieu of cytokines and
chemokine.
CTLA-4 is particularly critical for Treg function in spite of a number of distinct molecules that
are associated with Treg suppression. CTLA-4 is constitutively expressed on FoxP3+ Tregs, and
FoxP3 regulates its expression. The blockage of CTLA-4 abolishes Treg-mediated inhibition.
Moreover, fatal autoimmunity and inflammation appear in the germline removal as well as
Treg-specific conditional deficit of CTLA-4. The fate of responder T cells that are suppressed
by Tregs is also unclear, that is, whether they remain non-activated, die by apoptosis, or
become anergic. Additional studies are required to elucidate the molecular basis of suppres‐
sion mediated by Tregs.
Recent advances in the use of large-scale in vitro expansion of Tregs followed by in vivo re-
infusion of these cells raises the possibility that this strategy may be successfully utilized for
the treatments of autoimmune disorders. While cell-based therapies using Tregs are current‐
ly largely recognized in animal experimental tests, up to the present time, cell-based thera‐
pies using Tregs have not been clinically utilized in the suppression of autoimmune disorders.
There are numerous issues to be solved for using Tregs in humans, such as the requirement
for vigorous methods to separate and grow these cells. First, only low numbers of Tregs can
be harvested from the peripheral blood mononuclear cells (PBMCs). CD4 and CD25 have been
used to isolate Tregs for ex vivo expansion. CD4+CD25+ T cells are not homogenous and contain
both Tregs and conventional effector T cells (Teffs). Current expansion protocols activate both
Tregs and Teffs, and because it takes a longer time for Tregs to enter the S phase of cell cycle,
Teffs outgrow Tregs [54]. In addition, Tregs can lose suppressive activity after repetitive
stimulation with α-CD3 plus α-CD28 Abs with or without rIL-2 in vitro [55–57]. Second, despite
a growing number of published purification protocols for isolating subsets of Tregs, no
approach to date has demonstrated the capacity to isolate the entire Treg population with 100%
specificity from patients (the current clinical approach). Even FoxP3 or more recently Eos, a
transcriptional factor, considered the gold standard for identification of Tregs, is expressed
transiently in some activated non-regulatory human T cells [58], highlighting the difficulty in
both identifying and isolating a pure Treg population. Adoptive transfer of non-regulatory
Teffs with Tregs has a potential to worsen diseases. Third, gene transduction of CD4+ T cells
from PBMCs with Ag-specific TCR [59–61] or chimeric Ag receptor (CAR) [59–61, 63] elicits
generation of suppressive T-cell populations [64, 65] and overcomes the hurdle of the limited
numbers of Ag-specific T cells. Moreover, gene transduction of human PBMC with Ag-specific
TCR generated functional Ag-specific T cells, which targeted tissue-associated inflammation
[63]. However, the engineered Tregs express endogenous and exogenous polyclonal TCRs,
which may reduce their therapeutic potential (the current experimental approach) [66, 67].
Also, TCR mispairing is a concern with regard to the safety of TCR gene-transferred Tregs for
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clinical use, because the formation of new heterodimers of TCR can induce immunopatholo‐
gy [68]. Therefore, there is a need to improve this strategy and generate monoclonal Tregs.
Fourth, the differentiation state of Tregs is inversely related to their capacity to proliferate and
persist [69, 70]. The “right” Tregs resist terminal differentiation, maintain high replicative
potential (e.g., expression of common-γ chain − γc, CD132), are less prone to apoptosis (e.g.,
low expression of PD-1), and have a greater ability to respond to homeostatic cytokines [71],
which facilitates their survival. In addition, the “right” Tregs express high levels of mole‐
cules that facilitate their homing to lymph nodes (LNs), such as CD62L and CC-chemokine
receptors (e.g., CCR4, CCR7), and maintain stability or plasticity under certain inflammatory
conditions. Furthermore, after an effective immune response, the “right” Tregs persist in a
variety of differentiation states, providing protective immunity. Thus, the “right” Tregs are
the superior subsets for use in cell-based therapies. Finally, because there are too few cells,
harvesting sufficient numbers of tissue-associated Tregs from patients’ PBMC for TCR gene
transduction can be problematic.
Taken together, strong arguments support the development of Treg-based therapies in
autoimmune disorders using engineered Tregs. While clinical trials show the safety, feasibil‐
ity, and potential therapeutic activity of Treg-based therapies using this approach, concerns
about autoimmunity due to cross-reactivity with healthy tissues remain a major safety issue
[72, 73]. In addition, genetically modified Tregs using current approaches are usually inter‐
mediate or later effector Tregs [74], which only have short-term persistence in vivo.
6. Stem cell-derived Tregs
To date, stem cells are the only source available to generate a high number of the “right”
Tregs [75, 76]. It has been already demonstrated that induced pluripotent stem cell (iPSCs) are
like embryonic stem cells (ESCs) in different aspects, including the expression of definite stem
cell genes and proteins, doubling time, embryoid body formation, viable chimera formation,
potency and differentiability, chromatin methylation patterns, and teratoma formation [77].
However, the similarity between iPSCs and ESCs is still being assessed [78]. The generation
of iPSCs from the mouse and human somatic cells has garnered considerable attention.
Research has shown that iPSCs could be generated from the mouse and human somatic cells
by introducing Oct3/4 and Sox2 with either Klf4 and c-Myc or Nanog and Lin28 using
retroviruses or lentiviruses-mediated transduction [79–82]. Thus, iPSC technology continues
to progress rapidly, and clinically applicable iPSCs can be generated from patients with
noninvasive medical procedures. Many genetic methods as well as protein-based ap‐
proaches have been developed to produce iPSCs with potentially reduced risks, including that
of immunogenicity and tumorigenicity [83]. Because of the plasticity and the potential for an
unlimited capacity for self-renewal, iPSCs have great potential to be used in cell-based
therapies for autoimmune disorders comparable to ESCs and HSCs.
Previously, T cells have been demonstrated to be differentiated from ESCs and HSCs; recently
T cells [84] and Ag-specific CD8+ cytotoxic T lymphocytes (CTLs) [85] have been confirmed to
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be differentiated from iPSCs. In these investigations, the researchers genetically modified
mouse iPSCs with Ag (ovalbumin, OVA)-specific MHC II (I-Ab)-restricted TCR and FoxP3,
and then in vivo differentiated the iPSCs into functional Ag-specific CD4+ Tregs, which
dramatically prevented the mice from Ag-induced arthritis. Thus, a new approach to gener‐
ate a high number of functional Tregs from iPSCs may be used for the treatments of autoim‐
mune disorders. In fact, Ag-specific Tregs can be in vitro generated from iPSCs through a
Notch-mediated signaling. It has been shown that Ag-specific Tregs were generated from
iPSCs or ESCs genetically modified with the FoxP3 and Ag-specific TCR followed by stimu‐
lation with an in vitro Notch signaling. Furthermore, adoptive transfer of these stem cell-
derived Ag-specific Tregs had the ability to secrete a large amount of suppressive cytokines,
including TGF-β and IL-10, and suppressed autoimmunity [11, 75]. Additionally, forced
expression of Ag-specific TCR can suppress the expression of recombination-activating (Rag)
genes, resulting in a uniform expression of Ag-specific TCR on iPSC or ESC-derived Tregs. As
a result, this method has a potential to develop a great number of single-type Ag-specific Tregs.
Collectively, a large number of single-type Ag-specific Tregs can be generated by gene
transduction of iPSCs with Ag-specific TCR with FoxP3 followed by T lineage differentia‐
tion through an in vitro Notch signaling or an in vivo approach. The Ag-specific Tregs may be
applied for cell-based therapies of autoimmune disorders, such as T1D, and RA. Of note, these
stem cell-derived Ag-specific Tregs are less differentiated and have the ability to persist in vivo
after adoptive transfer. It can be predicted that the use of iPSCs as a mean to develop disease-
specific immune cells for immunotherapy has a great potential in the prevention of many
diseases. Therefore, iPSC-derived Ag-specific Tregs can be used in cell-based therapies for
autoimmune disorders.
7. Stem cell-derived Ag-specific Tregs for therapeutic use
Treatments of autoimmune disorders with Tregs have been shown to work in a number of
mouse models, such as T1D and RA. Tregs were activated with its cognate Ag and can suppress
the conventional Tregs within the immediate vicinity regardless of specificity [86]. Addition‐
ally, this suppressive function extends to a wide range of other immune cells such as B cells,
DCs, and monocytes, including naive, effector, and memory T cells. Ag specificity of Tregs is
important to counteract the ongoing autoimmunity because high doses of polyclonal anti‐
body may fail to keep in check autoimmune responses. Tregs require Ag specificity to home/
be retained at the appropriate site or tissue, and exert active suppression where Ag specifici‐
ty is chiefly determined by the individual TCR expressed. Under usual circumstances, a small
population of Ag-specific Tregs exists within a polyclonal population. For therapeutic
interventions, the generation of a large number of Ag-specific Tregs becomes essential.
Furthermore, existing Tregs in patients are insufficient to prevent the initiation of autoim‐
munity, it is questionable whether simply putting a large number of these cells back into the
patient, without modifying specificity or function, would have the desired effect. In addition,
Tregs specific to tissue/organ (e.g., joints, pancreas, intestine) facilitate stable FoxP3 expres‐
sion and avoid the induction of a potentially harmful systemic immunosuppression [87, 88].
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Therefore, in order for Tregs to be a viable treatment for autoimmune disorders, approaches
for generating the populations of Ag-specific Tregs are essential.
Previous studies have demonstrated the broad application of genetic manipulation of PSCs
for immunotherapy and have provided proof-of-principle data for using TCR gene-trans‐
duced PSCs for cell-based therapies [85, 89–91]. We also showed that functional iPSC-Treg
differentiates in vitro mediated through the Notch signaling [11, 75]. Murine iPSCs were
genetically modified with OVA-specific MHCII-restricted TCR (OTII) and FoxP3 by retrovi‐
rus-mediated transduction. Genetically modified iPSCs were stimulated with an in vitro Notch
ligand to direct iPSC differentiation into functional OVA-specific Tregs, which were able to
produce suppressive cytokines (TGF-β and IL-10), and inhibit other immune cell activities in
Figure 1. AIA in mice. Mice were immunized with methylated BSA (mBSA) followed by intra-articular knee re-chal‐
lenge with mBSA to induce T cell-mediated tissue damage. In each animal, one knee (right, Rt) was injected with
mBSA and OVA, and the contralateral control knee (left, Lt) was injected with mBSA only. As a result, the Ag-specific
Tregs just recognized the OVA Ag in the Rt knee. Conversely, the arthritis-inducing T cells recognized the mBSA Ag in
both knees. The data presented that while OVA was present (Rt knee), the transferred iPSC-derived Tregs essentially
reduced the inflammatory knee swelling, however, did not protect the control Lt knee in which only mBSA was inject‐
ed.
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vitro. In addition, adoptive transfer of Ag-specific iPSC-Tregs significantly suppressed the
development of autoimmunity in murine models.
Adoptive transfer of OVA-specific iPSC-Tregs in a well-established mouse model of Ag-
induced arthritis (AIA) inhibited the development of arthritis [11]. In this murine model,
arthritis was induced by intra-articular injection of methylated bovine serum albumin (mBSA)
into the knee (Rt). To direct the transferred cells to the knees, OVA was injected into one knee
and phosphate-buffered saline (PBS) was injected into the contralateral knee (Lt). Arthritis was
characterized by swelling of the synovium and damage of the cartilage around the joints
leading to the joint destruction (Figure 1). OVA-injected knees were protected from develop‐
ing arthritis, where PBS injected the knee developed severe arthritis (Figure 2). Particularly,
OVA-specific iPSC-Tregs infiltrate into the knee joints and maintain the Treg phenotype in
vivo (Figure 3). These results indicate that genetically modified iPSC-derived Tregs are tissue-
associated and are able to suppress autoimmune arthritis.
Figure 2. Ag-specific iPSC-Tregs ameliorate AIA in mice. Murine iPSCs transduced with the retroviral construct MiDR,
MiDR-FoxP3, or MiDR-TCR-FoxP3 and were cocultured on the OP9-DL1/DL4/I-Ab cells. On day 7, the gene-trans‐
duced cells (3 × 106/mouse) were i.v. adoptively transferred into C57BL/6 mice that were induced AIA 2 weeks later
after the cell transfer. On the following day of arthritis induction, arthritis severity was monitored by the measurement
of knee diameter. (A–C) % increase in knee diameter. (D) The mean scoring on day 7 for both knees from five mice.
Data are represented as the mean ± s.d. from three independent experiments (** p < 0.01, *** p < 0.001, two-way AN‐
OVA).
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Figure 3. Ag-specific iPSC-Tregs infiltrate into the knee joints and maintain the Treg phenotype in vivo. OVA-specific
iPSC-Tregs or nTregs (CD4+CD25+) from OT-II TCR transgenic mice (Thy1.2+) were i.v. adoptively transferred into
C57BL/6 congenic mice (Thy1.1+) with AIA. (A) Six weeks later, the popliteal lymph nodes (LNs) from the inflammato‐
ry right side were analyzed for CD4+ Thy1.2+ cells. The mean ± s.d. from three independent experiments is shown (* p <
0.05, one-way ANOVA). (B) On days 7–14 after arthritis induction, knees were removed and stained for immunohistol‐
ogy with FoxP3. The FoxP3+ cells (−) are indicated.
Adoptive transfer of OVA-specific iPSC-Tregs in a well-established mouse model of autoim‐
mune diabetes suppressed the development of diabetes. T1D is driven by self-reactive T cells
that infiltrate the pancreatic islets of Langerhans and induce the destruction of beta cells and
the loss of insulin production. This gradually causes pancreas to be unable to control blood
glucose levels. During the development of diabetes, the pancreatic islets release the beta cell
component that is occupied by immature DCs (IDC) in pancreatic islets. IDC carried the beta
cell component to the draining pancreatic lymph node, process the Ag, and present to CD4+ T
cells. T cell priming in lymph node leads to the expansion of circulating autoreactive T cells.
Following clonal expansion, autoreactive T cells express a number of adhesion molecules,
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including ICAM 1, the intercellular adhesion molecule 1, and LFA1, the lymphocyte func‐
tion-associated Ag 1 [92]. This allows the effector cells to home to the pancreatic islets. Once
they are in the pancreas, they activate inflammatory cells and causing insulitis (Figure 4). PSC-
derived Ag-specific Tregs have been used to cell-based therapies of autoimmune diabetes in
a murine model, RIP-mOVA × OT-I TCR F1 double transgenic mice. Mice will develop
autoimmune diabetes (blood glucose levels >250 mg/dl) when challenged with vaccina viruses
expressing OVA (VV-OVA). Adoptive transfer of OVA-specific iPSC-Trergs significantly
affected clinical outcome (Figure 5) by secreting IL-10 and TGF-β in the pancreas and reducing
the expression of ICAM 1. Particularly, adoptive transfer of OVA-specific iPSC-Tregs reduces
the number of inflammatory cells and protects beta cell destruction in the pancreas (Figure 6).
These results also suggest that genetically modified iPSC-derived Tregs are tissue-associated
and are able to suppress autoimmune diabetes.
Figure 4. Insulitis in autoimmune arthritis. During the development of diabetes, the pancreatic islets release the beta
cell component that is taken-up by IDC in pancreatic islets. IDC carried the beta cell component to the draining pancre‐
atic lymph node, process the Ag, and present to CD4+ T cells. T-cell priming in lymph nodes leads to the expansion of
circulating autoreactive T cells. Following clonal expansion, autoreactive T cells express a number of adhesion mole‐
cules, including ICAM 1, which allows the effector cells to home to the pancreatic islets. Once they are in the pancreas,
they activate inflammatory cells and causing insulitis.
Figure 5. Ag-specific iPSC-Tregs ameliorate autoimmune diabetes in mice. 3-week-old RIP-mOVA × OT-I F1 transgen‐
ic mice (n = 5/group) were i.p. injected with VV-OVA viruses and adoptively transferred with OVA-specific iPSC-
Tregs, non-specific iPSC-Tregs, or iPSC control. In the following weeks, the blood glucose levels were monitored by
measurement of blood glucose (*** p < 0.001, ** p < 0.01, one-way ANOVA).
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Figure 6. Adoptive transfer of Ag-specific iPSC-Tregs reduces the number of inflammatory cells and protects beta cell
destruction in the pancreas. At week 2 following T1D induction, the pancreases were removed, sectioned, and stained
with HE or insulin immunofluorescence. (A) Representative photomicrographs of HE staining. The cellular infiltra‐
tions (–) of inflammatory cells are indicated. (B) Representative photomicrographs by insulin immunoflurescent stain‐
ing. Insulin-secreting cells (–) are indicated. (C) Quantitation of beta cell colonies (insulitis scoring) in each group.
8. Future perspectives
T-cell–mediated suppression in immunologic tolerance still remains an exciting area of active
research in immunology. It has already been established that a unique Treg population is
engaged in the maintenance of immunologic self-tolerance. The natural development of such
Tregs will be the crucial for mediating the self-tolerance. However, Tregs are hard to define
phenotypically due to the lack of characteristic surface markers. Investigating the function and
development of Tregs will contribute to the understanding of immunologic self-tolerance and
shed light on the acquisition of autoimmune disorders. Published evidence showed that
human Tregs constitutively express high levels of FoxP3 and that mutations in FOXP3 results
in severe autoimmunity. This demonstrates that the expression of this transcription factor has
a key role in Treg function. Moreover, genetic modification of stem cells with FoxP3 for the
differentiation of Ag-specific Tregs can pave a way for new strategies for the treatment or
prevention of autoimmune diseases. However, preclinical data supporting the safety and
efficacy of gene therapy approaches is required to allow the transition from the bench to the
clinic.
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